Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma

CONCLUSIONSSunitinib and sorafenib might be associated with an increased risk of cardiovascular events and particularly stroke. Cancer 2015. © 2015 American Cancer Society.

Source: Cancer - October 6, 2015 Category: Cancer & Oncology Authors: Sekwon Jang, Chaoyi Zheng, Huei‐Ting Tsai, Alex Z. Fu, Ana Barac, Michael B. Atkins, Andrew N. Freedman, Lori Minasian, Arnold L. Potosky Tags: Original Article Source Type: research